1) Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Petta S, Cammà C, Di Marco V, Macaluso FS, Maida M, Pizzolanti G, Belmonte B, Cabibi D, Di Stefano R, Ferraro D, Guarnotta C, Venezia G, Craxì A. Liver Int. 2011 Apr;31(4):507-15.

2) Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: Don't forget the role of cyclosporin. Sinagra E, Orlando A, Renna S, Maida M, Cottone M. Inflamm Bowel Dis. 2011 Oct 29.

3) Causes of and prevention strategies for hepatocellular carcinoma. Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Semin Oncol. 2012 Aug;39(4):374-83.

4) Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study Cabibbo G, Maida M, Genco C, Parisi P, Peralta P, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V World J Hepatol 2012 September 27; 4(9): 256-261.

5) Treatment of hepatocellular carcinoma: present and future. Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. Expert Rev Anticancer Ther. 2013 Apr;13(4):469-79.

6) Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist. Macaluso FS, Maida M, Alessi N, Cabibbo G, Cabibi D. World J Hepatol. 2013 May 27;5(5):288-91.

7) Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. Future Oncol. 2013 Jun;9(6):845-54.

8) Progressive multi-organ expression of immunoglobulin G4-related disease: A case report. Maida M, Macaluso FS, Cabibbo G, Lo Re G, Alessi N. World J Hepatol. 2013 Jun 27;5(6):336-9.

9) Hepatobiliary and Pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis. Macaluso F, Maida M, Burgio MD, Brancatelli G. J Gastroenterol Hepatol. 2013 Aug;28(8):1257.

10) Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response. Cabibbo G, Maida M, Genco C, Alessi N, Peralta M, Butera G, Galia M, Brancatelli G, Genova C, Raineri M, Orlando E, Attardo S, Giarratano A, Midiri M, Di Marco V, Craxì A, Cammà C. PLoS One. 2013 Jul 29;8(7):e70016. doi: 10.1371/journal.pone.0070016. Print 2013.

11) Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. BioMed Research International 2013 http://dx.doi.org/10.1155/2013/564645.

12) Imaging appearance of treated hepatocellular carcinoma. Agnello F, Salvaggio G, Cabibbo G, Maida M, Lagalla R, Midiri M, Brancatelli G. World J Hepatol. 2013 Aug 27;5(8):417-24. doi: 10.4254/wjh.v5.i8.417.

13) Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients with Chronic HCV Genotype 1 Infection. Macaluso FS, Maida M, Cammà C, Cabibi D, Alessi N, Cabibbo G, Di Marco V, Craxì A, Petta S. Clin Gastroenterol Hepatol. 2013 Oct 7. pii: S1542-3565(13)01507-3.

14) Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Cabibbo G, Maida M, Cammà C, Craxì A. Expert Rev Anticancer Ther. 2013 Dec;13(12):1355-61. doi: 10.1586/14737140.2013.859989. Epub 2013 Nov 13.

15) Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, Almasio PL. World J Hepatol. 2013 Dec 27;5(12):685-91. doi: 10.4254/wjh.v5.i12.685.


16) Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. Maida M, Macaluso FS, Galia M, Cabibbo G. World J Hepatol. 2013 Dec 27;5(12):696-700. doi: 10.4254/wjh.v5.i12.696.

17) Staging systems of hepatocellular carcinoma: A review of literature. Maida M, Orlando E, Cammà C, Cabibbo G.  World J Gastroenterol. 2014 Apr 21;20(15):4141-4150.

18) Steatosis Affects the Performance of Liver Stiffness Measurement for Fibrosis Assessment in Patients with Genotype 1 Chronic Hepatitis C. Macaluso FS, Maida M, Cammà C, Cabibbo G, Cabibi D, Alduino R, Marco VD, Craxì A, Petta S. J Hepatol. 2014 Sep;61(3):523-9. doi: 10.1016/j.jhep.2014.04.045. Epub 2014 May 9.

19) Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. Licata A, Maida M, Cabibi D, Butera G, Macaluso FS, Alessi N, Caruso C, Craxì A, Almasio PL.Dig Liver Dis. 2014 Sep 12. pii: S1590-8658(14)00660-4. doi: 10.1016/j.dld.2014.08.040.

20) Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Iavarone M, Cabibbo G, Biolato M, Corte CD, Maida M, Barbàra M, Basso M, Vavassori S, Craxì A, Grieco A, Cammà C, Colombo M. Hepatology. 2015 Feb 2. doi: 10.1002/hep.27729.

21) The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Petta S, Maida M, Macaluso FS, Marco VD, Cammà C, Cabibi D, Craxì A. Hepatology. 2015 Apr 9. doi: 10.1002/hep.27844. [Epub ahead of print].

22) TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. Petta S, Maida M, Grimaudo S, Pipitone RM, Macaluso FS, Cabibi D, Cammà C, Di Marco V, Sferrazza S, Craxì A. Liver Int. 2015 Jul 17. doi: 10.1111/liv.12918. [Epub ahead of print]

23) Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. World J Hepatol. 2015 Aug 18;7(17):2053-7. doi: 10.4254/wjh.v7.i17.2053.

24) Hepatitis C Virus Infection is Associated With Increased Cardiovascular Mortality: A Meta-analysis of Observational Studies. Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. Gastroenterology. 2015 Sep 16. pii: S0016-5085(15)01322-0. doi: 10.1053/j.gastro.2015.09.007.

25) Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. Cabibbo G, Petta S, Maida M, Cammà C. Dig Dis. 2015 Sep;33(5):668-74. doi: 10.1159/000438477.

26) Genetic background in nonalcoholic fatty liver disease: A comprehensive review. Macaluso FS, Maida M, Petta S. World J Gastroenterol. 2015 Oct 21;21(39):11088-111.

27) Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I, Pinna AD, Golfieri R.  Liver Int. 2015 Nov 25. doi: 10.1111/liv.13029.

28) Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Aliment Pharmacol Ther. 2015 Dec 14. doi: 10.1111/apt.13485. [Epub ahead of print]

29) Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. Cabibi D, Bronte F, Porcasi R, Ingrao S, Giannone AG, Maida M, Grazia Bavetta M, Petta S, Di Marco V, Calvaruso V. Anal Cell Pathol (Amst). 2015;2015:431750. doi: 10.1155/2015/431750. Epub 2015 Nov 17.

30) Years of life that could be saved from prevention of hepatocellular carcinoma. Cucchetti A, Trevisani F, Bucci L, Ravaioli M, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Pinna AD; Italian Liver Cancer (ITA.LI.CA) group; Italian Liver Cancer ITA LI CA group.  Aliment Pharmacol Ther. 2016 Apr;43(7):814-24. doi: 10.1111/apt.13554. Epub 2016 Feb 11.

31) Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma. Maida M, Macaluso FS, Valenza F, Virdone R. J Gastrointestin Liver Dis. 2016 Jun;25(2):253-5.

32) Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. Renna S, Orlando E, Macaluso FS, Maida M, Affronti M, Giunta M, Sapienza C, Rizzuto G, Orlando R, Dimarco M, Cottone M, Orlando A. Aliment Pharmacol Ther. 2016 Aug;44(3):310-1.

33) Non-invasive assessment of liver injury in non-alcoholic fatty liver disease: a review of literature. Maida M, Macaluso FS, Salomone F, Petta  Curr Mol Med. 2016 Oct 4. [Epub ahead of print]

34) Screening and surveillance for hepatocellular carcinoma: perspective of a new era? Maida M, Malizia G, Affronti A, Virdone R, Maida C, Margherita V, D'Amico G. Screening  Expert Rev Anticancer Ther. 2016 Oct 12. [Epub ahead of print]

35) Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. Almasio PL, Licata A, Maida M, Macaluso FS, Costantino A, Alessi N, Grimaudo S, Accardi G, Caruso C, Craxi A. Hepat Mon. 2016 Oct 16;16(11):e31681.

36) Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants. Macaluso FS, Maida M, Renna S, Orlando E, Affronti M, Sapienza C, Dimarco M, Orlando R, Rizzuto G, Cottone M, Orlando A. Dig Liver Dis. 2016 Oct 14. pii: S1590-8658(16)30747-2. doi: 10.1016/j.dld.2016.10.001. [Epub ahead of print]

37) Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, Orlando E, Rizzuto G, Orlando R, Ventimiglia M, Cottone M, Orlando A. Scand J Gastroenterol. 2017 May 29:1-7.

38) Radiofrequency Ablation for Treatment of Refractory Gastric Antral Vascular Ectasia: A Systematic Review of the Literature. Maida M, Camilleri S, Manganaro M, Garufi S, Scarpulla G. Gastroenterol Res Pract. 2017;2017:5609647. doi: 10.1155/2017/5609647. Epub 2017 Aug 1.

39) Screening of colorectal cancer: present and future. Maida M, Macaluso FS, Ianiro G, Mangiola F, Sinagra E, Hold G, Maida C, Cammarota G, Gasbarrini A, Scarpulla G. Expert Rev Anticancer Ther. 2017 Oct 12. doi: 10.1080/14737140.2017.1392243.

40) New endoscopy advances to refine adenoma detection rate for colorectal cancer screening: None is the winner. Maida M, Camilleri S, Manganaro M, Garufi S, Scarpulla G. World J Gastrointest Oncol. 2017 Oct 15;9(10):402-406.

41) Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, De Santis A, Corte CD, Maida M, Attili AF, Sangiovanni A, Cammà C, La Torre G, Gasbarrini A, Grieco A. Ann Hepatol. 2017 Dec 27;17(1):110-118. doi: 10.5604/01.3001.0010.7542.
 
42) Faecal Microbiota Transplantation as Emerging Treatment in European Countries. Maida M, Mcilroy J, Ianiro G, Cammarota G. Adv Exp Med Biol. 2018;1050:177-195. doi: 10.1007/978-3-319-72799-8_11.

43) Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact? Maida M, Cabibbo G, Cammà C. Expert Rev Anticancer Ther. 2018 Feb 21.

44) Binge Drinking among adolescents is related to the development of Alcohol Use Disorders: results from a Cross-Sectional Study. Addolorato G, Vassallo GA, Antonelli G, Antonelli M, Tarli C, Mirijello A, Agyei-Nkansah A, Mentella MC, Ferrarese D, Mora V, Barbàra M, Maida M, Cammà C, Gasbarrini A; Alcohol Related Disease Consortium. Sci Rep. 2018 Aug 22;8(1):12624. doi: 10.1038/s41598-018-29311-y.

45) Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis. Ianiro G, Maida M, Burisch J, Simonelli C, Hold G, Ventimiglia M, Gasbarrini A, Cammarota G. United European Gastroenterol J. 2018 Oct;6(8):1232-1244. doi: 10.1177/2050640618780762. Epub 2018 Jun 3.

46) Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. Macaluso FS§, Maida M§, Ventimiglia M, Renna S, Cottone M, Orlando A.  Inflamm Bowel Dis. 2018 Dec 22. doi: 10.1093/ibd/izy365.

47) Quality measures improving endoscopic screening of colorectal cancer: a review of the literature. Maida M, Morreale G, Sinagra E, Ianiro G, Margherita V, Cirrone Cipolla A, Camilleri S. Expert Rev Anticancer Ther. 2019 Jan 7. doi: 10.1080/14737140.2019.1565999.

48) Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? Cabibbo G, Rossi M, Celsa C, Maida M, Cammà C. Recenti Prog Med. 2018 Dec;109(12):605-608. doi: 10.1701/3082.30746.

49) Safety of NER1006. Maida M. Gastrointest Endosc. 2019 Sep;90(3):540-541. doi: 10.1016/j.gie.2019.04.213.

50) Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease in Real-life Experiences: A Meta-analysis of Observational Studies. Macaluso FS§, Maida M§, Ventimiglia M, Cottone M, Orlando A. Expert Opin Biol Ther. 2019 Dec 20.

51) Incidence of hepatocellular carcinoma after HCV eradication: assessing the risk. Maida M, Macaluso FS. Hepatobiliary Surg Nutr. 2020;9(2):255‐256. doi:10.21037/hbsn.2019.10.17

52) Current challenges and future needs of clinical and endoscopic training in gastroenterology: a European survey. Maida M, Alrubaiy L, Bokun T, Bruns T, Castro V, China L, Conroy G, Trabulo D, Van Steenkiste C, Voermans RP, Burisch J, Ianiro G. Endosc Int Open. 2020 Apr;8(4):E525-E533. doi: 10.1055/a-1093-0877. Epub 2020 Mar 23.

53) Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study. Maida M, Sinagra E, Morreale GC, Sferrazza S, Scalisi G, Schillaci D, Ventimiglia M, Macaluso FS, Vettori G, Conoscenti G, Di Bartolo C, Garufi S, Catarella D, Manganaro M, Virgilio CM, Camilleri S. World J Gastroenterol. 2020 Apr 28;26(16):1950-1961. doi: 10.3748/wjg.v26.i16.1950.

54) Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: a national survey. Maida M, Sferrazza S, Savarino E, Ricciardiello L, Repici A, Morisco F, Furnari M, Fuccio L, Morreale GC, Vitello A, Burra P, Marchi S, Annibale B, Benedetti A, Alvaro D, Ianiro G; Italian Society of Gastroenterology (SIGE). Dig Liver Dis . 2020 May 16.  doi: 10.1016/j.dld.2020.05.017.  Online ahead of print.

55) Tenapanor for the treatment of irritable bowel syndrome with constipation. Sinagra E, Rossi F, Raimondo D, Conoscenti G, Anderloni A, Guarnotta V, Maida M. Expert Rev Clin Pharmacol. 2020;1‐7. doi:10.1080/17512433.2020.1762570.

56) Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey. Marasco G, Nardone OM, Maida M, Boskoski I, Pastorelli L, Scaldaferri F; Italian Association of Young Gastroenterologist and Endoscopist (AGGEI). Dig Liver Dis. 2020 May 23:S1590-8658(20)30233-4. doi: 10.1016/j.dld.2020.05.023. Epub ahead of print. PMID: 32507619

57) Management of antiplatelet or anticoagulant therapy in endoscopy: A review of literature. Maida M, Sferrazza S, Maida C, Morreale GC, Vitello A, Longo G, Garofalo V, Sinagra E. World J Gastrointest Endosc. 2020 Jun 16;12(6):172-192. doi: 10.4253/wjge.v12.i6.172. PMID: 32843928; PMCID: PMC7415229.

58) Effectiveness and safety of NER1006 versus standard bowel preparations: A meta-analysis of randomized phase-3 clinical trials. Maida M, Macaluso FS, Sferrazza S, Ventimiglia M, Sinagra E.  Dig Liver Dis. 2020;S1590-8658(20)30252-8. doi:10.1016/j.dld.2020.05.046. [published online ahead of print, 2020 Jun 22].

59) New Therapeutic Molecules and their Metabolism in Gastroenterology. Nakov R, Maida M, Ianiro G. Curr Drug Metab. 2020;21(4):246. doi:10.2174/138920022104200615111932.

60) Screening of gastrointestinal cancers during COVID-19: a new emergency. Maida M. Lancet Oncol. 2020;21(7):e338. doi:10.1016/S1470-2045(20)30341-7.

61) Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. Vitello A, Shahini E, Macaluso FS, Morreale GC, Sinagra E, Pallio S, Maida M. Expert Rev Anticancer Ther. 2020 Aug 18. doi: 10.1080/14737140.2020.1813030. Epub ahead of print. PMID: 32811225.

62) Effectiveness and safety of underwater techniques in gastrointestinal endoscopy: a comprehensive review of the literature. Maida M, Sferrazza S, Murino A, Lisotti A, Lazaridis N, Vitello A, Fusaroli P, de Pretis G, Sinagra E. Surg Endosc. 2020 Aug 27. doi: 10.1007/s00464-020-07907-8. Epub ahead of print. PMID: 32856154.

63) GI Training in the COVID-19 Era: A Problem of Global Concern. Marasco G, Maida M. Dig Dis Sci. 2020;10.1007/s10620-020-06578-8. doi:10.1007/s10620-020-06578-8.

64) Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature. Rogger TM, Michielan A, Sferrazza S, Pravadelli C, Moser L, Agugiaro F, Vettori G, Seligmann S, Merola E, Maida M, Ciarleglio FA, Brolese A, de Pretis G. World J Gastroenterol. 2020 Sep 21;26(35):5375-5386. doi: 10.3748/wjg.v26.i35.5375.

65) Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. Furnari M, Eusebi LH, Savarino E, Petruzzellis C, Esposito G, Maida M, Ricciardiello L, Pecere S, Buda A, De Bona M, Spada C, Di Giulio E, Costamagna G, Boskoski I, Giannini EG; Young-ENDO-ITA Study Group. Gut. 2020 Sep 28:gutjnl-2020-323116. doi: 10.1136/gutjnl-2020-323116. Epub ahead of print. PMID: 32989018; PMCID: PMC7523174.

66) Use of artificial intelligence in improving adenoma detection rate during colonoscopy: Might both endoscopists and pathologists be further helped. Sinagra E, Badalamenti M, Maida M, Spadaccini M, Maselli R, Rossi F, Conoscenti G, Raimondo D, Pallio S, Repici A, Anderloni A. World J Gastroenterol. 2020 Oct 21;26(39):5911-5918. doi: 10.3748/wjg.v26.i39.5911. PMID: 33132644.